CAMBRIDGE, Mass., (March 24, 2026) — Insilico Medicine (3696.HK) is proud to have been named to Fast Company ’s prestigious list of the World’s Most Innovative Companies and the #3 Most Innovative Biotech Company of 2026. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World’s 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions.
Insilico Medicine was recognized for demonstrating real-world clinical impact from its generative AI platform while achieving significant commercial and capital markets milestones. In 2025, the company reported Phase IIa results for rentosertib, the first wholly AI-discovered and AI-designed small-molecule drug, showing stabilization or improvement in lung function in patients with idiopathic pulmonary fibrosis and a favorable safety profile. In parallel, Insilico advanced multiple AI-designed programs across clinical and preclinical stages and expanded a portfolio of strategic collaborations with global pharmaceutical partners. The company’s momentum was further underscored by its successful public listing on the Hong Kong Stock Exchange, completing the largest biotech IPO in Hong Kong in 2025.
“We’re honored to be recognized by Fast Company as one of the world’s most innovative companies. This distinction reflects the strength of our end-to-end AI platform and our ability to translate computational discovery into a growing clinical pipeline,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “We believe this is just the beginning of a new era where generative AI fundamentally reshapes how medicines are created.”
As a pioneer in generative artificial intelligence application for drug discovery, Insilico continues to drive deep integration of cutting-edge AI technology with extensive scientific expertise, building a diversified internal pipeline covering over 40 innovative programs and 28 drug candidates at the IND-enabling stage, of which 12 have received IND clearance.
Beyond small molecule drug innovation, Insilico is also expanding diverse applications of generative AI. Leveraging Generative Biologics, the biomolecule engineering engine under Pharma.AI, the company continues to empower the development of new modalities in therapeutics including peptides, nanobodies, antibody-drug conjugates (ADCs), and PROTACs. In addition, Insilico’s MMAI Gym, a specialized training environment designed for biochemistry and other high-barrier specialized domains, was recently launched with the purpose of equipping frontier large language models (LLMs) with stronger professional reasoning and capabilities across expert tasks.
The World’s Most Innovative Companies is Fast Company ’s hallmark franchise and one of its most anticipated editorial efforts of the year. To determine honorees, Fast Company’ s editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world.
“Our list of the Most Innovative Companies is about spotlighting organizations that don’t just adapt to change—they drive it,” said Brendan Vaughan, editor-in-chief of Fast Company . “The companies we honor this year are redefining what leadership looks like in 2026, pairing bold ideas with measurable impact and turning breakthrough innovation into real-world value. They are setting the pace for their industries and offering a blueprint for what sustained innovation can achieve.”
The full list of Fast Company’s Most Innovative Companies honorees can now be found at fastcompany.com . It will also be available on newsstands beginning March 31, 2026.
Fast Company will host the Most Innovative Companies Summit and Gala for honorees on May 19 in New York City. The summit features a day of inspiring content, followed by a creative black-tie gala including networking, a seated dinner, and an honoree presentation.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code HKEX: 03696.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
ABOUT FAST COMPANY
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with fellow business publication Inc. For more information, please visit fastcompany.com .